Evofem Biosciences Terminates Key Manufacturing Agreement for PHEXXI® Due to Supplier Failure
EVFM sits 23% above its 52-week low of $0.007 on light trading volume (0.2× avg).
Summary
Evofem Biosciences terminated a critical manufacturing and supply agreement for its PHEXXI® product due to the supplier's inability to establish production, adding operational challenges to a company already facing severe financial distress.
Key Events · Legal and Risk Events · EVFM
-
Termination of Key Manufacturing Agreement
Evofem Biosciences, Inc. and Windtree Therapeutics, Inc. mutually agreed to terminate their License and Supply Agreement, originally established in March 2025, effective March 13, 2026.
-
Supplier Failed to Establish Manufacturing
The termination was due to Windtree Therapeutics' inability to establish the manufacturing capabilities required to produce PHEXXI® in accordance with the agreement terms.
-
No Termination Fees
The termination agreement specifies that no termination or other fees are payable by either party in connection with the cessation of the agreement.
-
Operational Setback for Distressed Company
This event represents a significant operational challenge for Evofem, which recently disclosed a going concern warning and critical liquidity issues in its March 11, 2026 10-K filing, impacting its ability to secure product supply.
Analysis · EVFM · Life Sciences
Evofem Biosciences has terminated its License and Supply Agreement with Windtree Therapeutics, Inc., which was intended to establish Windtree as a manufacturer and supplier of PHEXXI®. The termination, effective March 13, 2026, was mutually agreed upon because Windtree failed to establish the necessary manufacturing capabilities. While no termination fees are payable, this operational setback is significant for Evofem, especially given its recent 10-K filing on March 11, 2026, which disclosed a going concern warning, critical liquidity issues, and severe financial distress. The inability to secure a reliable manufacturing partner for its key product further complicates the company's efforts to generate revenue and address its precarious financial position.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVFM was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.01 to $0.02. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.